A Liver Transplant Patient on Everolimus Treatment Presented with Acute Anterior Myocardial Infarction: Does the Type of Drug-eluting Stent Matter?

摘要

Liver transplantation (LT) is the most effective managementstrategy for end-stage liver disease and hepatocellular carcinoma(1). Owing to the evolution of surgical techniques along withpotent immunosuppressive agents and infection control, survivalrates following LT have reached 90% and 80% at one and fiveyears, respectively (1). In the general population, cardiovasculardisease (CVD) constitutes the most common cause of adverseclinical outcomes in patients undergoing LT in the long-term(2). Primary percutaneous coronary intervention (PCI) is therecommended therapeutic strategy for ST-elevation myocardialinfarction (STEMI) in post-LT patients (3). However, there existno specific recommendations in the current literature regardingthe most preferable type of drug-eluting stent (DES) during PCIin patients receiving long-term systemic immunosuppressivetherapy.